Brief: Kintor Pharma Says Unit Entered Proxalutamide Licensing Agreement

Kintor Pharmaceutical

15/07/2021 02:51

July 15 (Reuters) - Kintor Pharmaceutical Ltd  9939.HK :
    * UNIT ENTERED PROXALUTAMIDE LICENSING AGREEMENT WITH
SHANGHAI
FOSUN PHARMACEUTICAL DEVELOPMENT
    * FOSUN PHARMA DEVELOPMENT WILL BE GRANTED EXCLUSIVE RIGHTS
OF
REGISTRATION AND COMMERCIALISATION OF PROXALUTAMIDE IN
COLLABORATION REGIONS
    * WILL BE ELIGIBLE TO RECEIVE UPFRONT AND MILESTONE PAYMENTS
UP TO
RMB560 MILLION
    * CO WILL ALSO BE ELIGIBLE TO RECEIVE ROYALTY PAYMENTS THAT
ARE
NOT LESS THAN 50% OF TOTAL OPERATING PROFIT IN COLLABORATION
REGIONS
    * KINTOR PHARMACEUTICAL COLLABORATES WITH FOSUN PHARMA
DEVELOPMENT
TO COMMERCIALISE PROXALUTAMIDE FOR TREATMENT OF COVID-19 IN
INDIA AND AFRICA

Source text for Eikon:  ID:nHKS5dYXzp 
Further company coverage:  600196.SS   9939.HK 

 ((Reuters.Briefs@thomsonreuters.com;))